INAB Stock Price, IN8bio Inc Quote, Chart

Market Summary

USD1.03+0.01

Market Closed

0.98%

INAB Stock Price

View Fullscreen

INAB RSI Chart

INAB Valuation

Market Cap

45.4M

Price/Earnings (Trailing)

-1.46

Price/Free Cashflow

-1.87

INAB Price/Earnings (Trailing)

INAB Profitability

Return on Equity

-177.13%

Return on Assets

-92.09%

Free Cashflow Yield

-53.42%

INAB Fundamentals

INAB Earnings

Earnings (TTM)

-31.0M

Earnings Growth (Yr)

-13.78%

Earnings Growth (Qtr)

-12.69%

Breaking Down INAB Revenue

Last 7 days

2.0%

Last 30 days

3%

Last 90 days

-7.2%

Trailing 12 Months

-67.3%

How does INAB drawdown profile look like?

INAB Financial Health

Current Ratio

4.57

INAB Investor Care

Shares Dilution (1Y)

48.31%

Diluted EPS (TTM)

-0.91

Tracking the Latest Insider Buys and Sells of IN8bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 13, 2023	graff jeremy r.	acquired	-	-	2,049	-
Dec 13, 2023	brandt peter c.	acquired	-	-	81,967	-
Dec 13, 2023	roemer alan s.	acquired	-	-	102,459	-
Dec 13, 2023	lamb lawrence	acquired	-	-	1,639	evp and cso
Dec 13, 2023	ho william tai-wei	acquired	-	-	81,967	president and ceo
Dec 13, 2023	epperly corinne	acquired	-	-	81,967	-
Dec 13, 2023	mccall patrick	acquired	-	-	20,492	chief financial officer
Dec 13, 2023	goswami trishna	acquired	-	-	4,098	chief medical officer
Dec 13, 2023	rochlin kate	acquired	-	-	12,295	chief operating officer
Sep 13, 2023	graff jeremy r.	bought	2,375	0.95	2,500	-

Which funds bought or sold INAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-11,849	69,910	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-27,334	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	13,702	13,702	-%
May 15, 2024	Royal Bank of Canada	reduced	-82.2	-	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	31.93	13,839	121,896	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-1.89	-9,407	49,003	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	38,417	38,417	-%
May 15, 2024	683 Capital Management, LLC	unchanged	-	-122,951	725,410	0.05%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	20,717	20,717	-%
May 15, 2024	Alyeska Investment Group, L.P.	reduced	-45.59	-596,652	526,299	-%

Are Funds Buying or Selling INAB?

Are funds buying INAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INAB

No. of Funds

Unveiling IN8bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	ho william tai-wei	7.1%	3,126,505	SC 13G/A
Dec 15, 2023	hirschman orin	9.4%	4,098,361	SC 13G
Dec 15, 2023	bios fund ii, lp	1.3%	574,432	SC 13D/A
Dec 15, 2023	transcend partners opportunity fund i llc	7.5%	3,222,485	SC 13G/A
Aug 11, 2023	transcend partners opportunity fund i llc	13.0%	4,111,958	SC 13G
Aug 11, 2023	ho william tai-wei	9.1%	2,900,899	SC 13G

Recent SEC filings of IN8bio Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 07, 2024	424B5	Prospectus Filed
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to IN8bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

IN8bio Inc News

Latest updates

IN8bio Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	28.6%	34.00	26.00	30.00	25.00	33.00	38.00	31.00	37.00	42.00	47.00	18.00	21.00
Current Assets	48.8%	25.00	17.00	19.00	14.00	22.00	30.00	27.00	33.00	39.00	44.00	12.00	18.00
Cash Equivalents	64.3%	22.00	13.00	17.00	11.00	18.00	28.00	26.00	32.00	37.00	41.00	12.00	18.00
Net PPE	-6.0%	4.00	4.00	4.00	4.00	4.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	3.8%	9.00	8.00	8.00	8.00	10.00	9.00	4.00	4.00	4.00	4.00	4.00	3.00
Current Liabilities	15.1%	5.00	5.00	4.00	4.00	6.00	5.00	3.00	2.00	2.00	2.00	3.00	3.00
Shareholder's Equity	40.4%	25.00	18.00	22.00	17.00	23.00	30.00	27.00	33.00	38.00	43.00	-	-
Retained Earnings	-9.1%	-91.22	-83.62	-76.45	-68.74	-61.21	-53.41	-46.01	-38.84	-32.69	-26.84	-23.45	-18.04
Additional Paid-In Capital	14.6%	116	101	98.00	86.00	84.00	83.00	73.00	72.00	71.00	70.00	2.00	1.00
Shares Outstanding	35.4%	43.00	32.00	31.00	25.00	25.00	20.00	19.00	19.00	19.00	7.00	4.00	4.00
Float	-	-	-	23.00	-	-	-	6.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-63.3%	-7,919	-4,850	-5,713	-5,338	-7,439	-7,949	-5,741	-5,872	-4,559	-2,176	-6,365	-2,461	-2,507	-	-	-
Share Based Compensation	-1.0%	1,240	1,252	1,240	1,019	859	922	897	884	764	965	477	392	361	303	16.00	20.00
Cashflow From Investing	1.4%	-71.00	-72.00	-77.00	-22.00	-429	-1,263	-1,764	-425	-253	-156	-	-	-	-	-	-
Cashflow From Financing	-102.1%	-277	13,352	1,652	11,493	547	-253	9,410	-67.00	-102	-1,212	35,194	-592	-435	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INAB Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,903	$ 4,385
General and administrative	3,742	3,470
Total operating expenses	8,645	7,855
Interest income	83	0
Other Income	0	330
Loss from operations	(8,562)	(7,525)
Net loss	$ (8,562)	$ (7,525)
Net loss per share attributable to common stockholders - basic	$ (0.2)	$ (0.3)
Net loss per share attributable to common stockholders - diluted	$ (0.2)	$ (0.3)
Weighted-average number of shares used in computing net loss per common share, basic	43,287,325	24,732,580
Weighted-average number of shares used in computing net loss per common share, diluted	43,287,325	24,732,580

INAB Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 13,015		$ 10,860
Prepaid expenses and other current assets	2,740	$ 3,343
Non-current assets
Property and equipment, net	3,325	3,514
Restricted cash	256		253
Current liabilities
Accrued expenses and other current liabilities	895	2,955
Short-term finance lease liability	680
Short-term operating lease liability	856
Long-term finance lease liability	351
Long-term operating lease liability	3,828
Stockholders' Equity
Total Stockholders' Equity	$ 17,526	$ 24,937	$ 16,788	$ 22,732

About IN8bio Inc

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

CEO	Mr. Tai-Wei Ho
WEBSITE	https://in8bio.com
INDUSTRY	Biotechnology
EMPLOYEES	29

IN8bio Inc Frequently Asked Questions

What is the ticker symbol for IN8bio Inc? What does INAB stand for in stocks?

INAB is the stock ticker symbol of IN8bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of IN8bio Inc (INAB)?

As of Fri May 17 2024, market cap of IN8bio Inc is 45.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INAB stock?

You can check INAB's fair value in chart for subscribers.

What is the fair value of INAB stock?

You can check INAB's fair value in chart for subscribers. The fair value of IN8bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of IN8bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is IN8bio Inc a good stock to buy?

The fair value guage provides a quick view whether INAB is over valued or under valued. Whether IN8bio Inc is cheap or expensive depends on the assumptions which impact IN8bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INAB.